NervGen Pharma recently announced an underwritten public offering of 24 million common shares. The shares, being sold at a public offering price of US$2.50 each, includes an accompanying warrant with an exercise price of US$3.68 per common share that is immediately exercisable from the date of issuance with a five years expiry. The Vancouver-based clinical-stage […]